Carboplatin
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Carboplatin: From Ovarian Cancer to Female Breast Carcinoma
One-Sentence Summary
Carboplatin is a platinum-based chemotherapy drug originally used to treat ovarian cancer and related ovarian tumour types. The TxGNN model predicts it may be effective for female breast carcinoma, particularly triple-negative and HER2-positive subtypes. Evidence is substantial: 44 clinical trials (including 3 Phase 3 trials) and 20 publications (including several randomised trials) support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovarian cancer (including ovarian adenocarcinoma, germ cell tumours and carcinosarcoma) |
| Predicted New Indication | Female breast carcinoma |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L1 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, carboplatin is a DNA-crosslinking platinum agent that causes DNA damage and triggers apoptosis (programmed cell death) in cancer cells.
Tumours with homologous recombination deficiency (HRD), such as BRCA1/2-associated and triple-negative breast cancers, are particularly vulnerable to this kind of DNA damage. Ovarian and breast cancers share BRCA/HRD biology, which is the main link between the original indication and the predicted one. The same cytotoxic mechanism that underlies carboplatin's ovarian cancer use may therefore apply to these breast cancer subtypes.
Clinical practice supports this reasoning. Carboplatin is already used in breast cancer regimens, such as docetaxel-carboplatin-trastuzumab combinations for HER2-positive disease and added to neoadjuvant chemotherapy for triple-negative disease. Results are not uniformly positive, however: one recent report notes that adding carboplatin gave no survival benefit in an early triple-negative trial (NRG-BR003), and that omitting carboplatin in HER2-positive early disease preserved efficacy with better tolerability.
Clinical Trial Evidence
The data include many trials; the most relevant are listed below.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00321633 | Phase 2 | Completed | 148 | Randomised carboplatin vs docetaxel in metastatic genetic (BRCA) breast cancer |
| NCT00021255 | Phase 3 | Completed | 3222 | Adjuvant AC-T, AC-TH vs docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive operable breast cancer |
| NCT00047255 | Phase 3 | Completed | 263 | Docetaxel + trastuzumab with or without carboplatin as first-line therapy in HER2-amplified advanced breast cancer |
| NCT02125344 | Phase 3 | Completed | 961 | GeparOcto: dose-dense, dose-intensified neoadjuvant regimens, one including carboplatin, in high-risk early breast cancer |
| NCT00025688 | Phase 3 | Unknown | N/A | Weekly paclitaxel with or without carboplatin in women aged 65+ with metastatic breast cancer |
| NCT00616967 | Phase 2 | Active, not recruiting | 68 | Carboplatin + nab-paclitaxel with or without vorinostat as preoperative therapy in HER2-negative breast cancer |
| NCT01208480 | Phase 2 | Completed | 45 | Neoadjuvant bevacizumab, docetaxel and carboplatin in triple-negative breast cancer |
| NCT00003612 | Phase 2 | Completed | 92 | Paclitaxel, carboplatin and trastuzumab first-line in HER2-overexpressing metastatic breast cancer |
| NCT06291064 | Phase 2 | Recruiting | 85 | Epirubicin/cyclophosphamide followed by docetaxel + carboplatin in Nigerian women with triple-negative breast cancer |
| NCT01445418 | Phase 1 | Completed | 103 | Olaparib + carboplatin in BRCA1/2 carriers and triple-negative breast cancer |
The first and second trials listed are the most directly informative; many of the others test add-on agents with carboplatin as part of the backbone, so they speak more to feasibility than to carboplatin's own contribution.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24794243 | 2014 | RCT | Lancet Oncol | GeparSixto: adding carboplatin to neoadjuvant therapy in triple-negative and HER2-positive early breast cancer |
| 29501363 | 2018 | RCT | Lancet Oncol | BrighTNess: veliparib plus carboplatin or carboplatin alone added to neoadjuvant chemotherapy in triple-negative breast cancer |
| 35044810 | 2022 | RCT | J Clin Oncol | CALGB 40603: long-term outcomes with or without carboplatin and bevacizumab in triple-negative breast cancer |
| 33208340 | 2021 | RCT | Clin Cancer Res | NeoSTOP: anthracycline-free vs anthracycline-containing neoadjuvant carboplatin regimens in triple-negative breast cancer |
| 41436191 | 2025 | RCT | BMJ | CITRINE: adjuvant carboplatin-intensified vs standard chemotherapy in high-risk early triple-negative breast cancer |
| 41115255 | 2026 | RCT | J Clin Oncol | Phase 3 trial adding carboplatin to taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer |
| 40593759 | 2025 | RCT | Nat Commun | ARX788 + pyrotinib vs standard TCbHP (docetaxel, carboplatin, trastuzumab, pertuzumab) in HER2-positive disease |
| 29175149 | 2018 | RCT | Lancet Oncol | KRISTINE: trastuzumab/pertuzumab with chemotherapy vs T-DM1 plus pertuzumab in HER2-positive disease |
| 39631485 | 2024 | Review | Pharmacol Res | Review of targeted and cytotoxic inhibitors used in breast cancer treatment |
| 16720915 | 2006 | Review | Med Oncol | Paclitaxel-carboplatin combination in advanced breast cancer: evidence for synergy, efficacy and safety |
Several of these randomised trials report that adding carboplatin raises pathological complete response rates in triple-negative disease, though the survival benefit is less consistent, and recent reports describe controversy in this setting.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16203P | Kemocarb Concentrate for Solution for Infusion 10 mg/ml | Infusion, solution concentrate | Not stated in the data |
| SIN02301P | DBL Carboplatin Injection 10 mg/ml | Injection | Not stated in the data |
| SIN10356P | Carbotinol Injection 50 mg/5 ml | Injection | Not stated in the data |
All three registrations are valid single-ingredient products, and there are no cancelled licences.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (platinum-based DNA-crosslinking agent) |
| Myelosuppression Risk | High (the contraindication data link carboplatin to thrombocytopenia, neutropenia, leukopenia and anaemia) |
| Emetogenicity Classification | Moderate |
| Monitoring Items | Complete blood count with differential, liver and renal function, hearing and peripheral neuropathy assessment |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Disease-level contraindication signals (from the TxGNN knowledge graph, not label text): kidney disease, liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, leukopenia, anaemia, blood coagulation disease, peripheral neuropathy and peripheral nervous system disease, hearing and auditory system disorders.
- Drug Interactions: 100 interactions were found. Most listed are moderate, including:
- Proton pump inhibitors (rabeprazole, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole)
- Aminoglycosides and related antibiotics (kanamycin, neomycin, streptomycin, vancomycin)
- Metronidazole and tinidazole
- Statins (rosuvastatin, simvastatin)
Levofloxacin is minor, and several others (e.g. calcitriol, glimepiride, mesalazine) are of unknown severity.
Package insert warnings and contraindications were not available in the compiled data. Please refer to the package insert for label-level safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple randomised trials, including Phase 3 trials and several Phase 2 RCTs, support carboplatin use in breast cancer, especially triple-negative and HER2-positive subtypes, and the drug is already marketed in Singapore. The guardrails are needed because the benefit is subtype-dependent, survival gains are inconsistent (some recent data show no benefit), and many of the Phase 3 trials test add-on agents rather than carboplatin alone.
To proceed, the following is needed:
- Singapore package insert warnings, contraindications and approved indication text, which are missing from the registration data
- Detailed mechanism of action data
- Subtype-specific review (triple-negative, BRCA/HRD-positive, HER2-positive) to define the target population
- A haematological and toxicity monitoring plan, including for patients with renal, hepatic or neuropathic comorbidity
- Review of drug interaction risks, especially with nephrotoxic and ototoxic agents
Other predicted indications (for context):
- Endometrial mixed adenocarcinoma: Proceed with Guardrails (L1). Two Phase 3 trials use carboplatin/paclitaxel as the backbone, but they test add-on agents.
- Adult germ cell tumour: Research Question (L2). Cisplatin remains the preferred standard, and carboplatin evidence comes mostly from Phase 1/2 high-dose and relapsed-disease studies.
- Cervical and endometrial mucinous adenocarcinoma: Research Question (L3). Evidence is limited to small Phase 1 trials and case reports.
- Rectum, colon, gallbladder and extrahepatic bile duct mucinous adenocarcinoma, and villoglandular endometrial endometrioid adenocarcinoma: Hold (L5). These predictions rest on ontology similarity, with no supporting trials or relevant literature.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.